CN104707047B - A kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof - Google Patents
A kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof Download PDFInfo
- Publication number
- CN104707047B CN104707047B CN201510170402.0A CN201510170402A CN104707047B CN 104707047 B CN104707047 B CN 104707047B CN 201510170402 A CN201510170402 A CN 201510170402A CN 104707047 B CN104707047 B CN 104707047B
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- pulmonary carcinoma
- rhizoma
- ganoderma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 36
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 241000222336 Ganoderma Species 0.000 claims abstract description 32
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 22
- 241000756943 Codonopsis Species 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 12
- 241001057584 Myrrha Species 0.000 claims abstract description 11
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 11
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 241000195474 Sargassum Species 0.000 claims abstract description 11
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960001285 quercetin Drugs 0.000 claims abstract description 11
- 235000005875 quercetin Nutrition 0.000 claims abstract description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 26
- 238000001816 cooling Methods 0.000 claims description 14
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 235000014347 soups Nutrition 0.000 claims description 7
- 229940032094 squalane Drugs 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- 229940082509 xanthan gum Drugs 0.000 claims description 7
- 235000010493 xanthan gum Nutrition 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- -1 twice Substances 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000013296 A/J mouse Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to technical field of Chinese medicine, be specifically related to a kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof.Pharmaceutical pack is containing following component: Ganoderma, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, natural Calculus Bovis, Radix Ophiopogonis, Herba Scutellariae Barbatae, Quercetin, Rhizoma Sparganii, Sargassum, Myrrha, Herba Agrimoniae, the Rhizoma Pinelliae, Fructus Forsythiae, Herba Solani Lyrati, Pumex and Semen Armeniacae Amarum.Dosage of the present invention is little, and treatment cycle is short, effectively can suppress, treat pulmonary carcinoma.
Description
Technical field
The invention belongs to technical field of Chinese medicine, be specifically related to a kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof.
Background technology
It is the fastest that pulmonary carcinoma is that M & M increases, to one of population health and the maximum malignant tumor of life threat.The many countries of immediate and mid-term all report that the M & M of pulmonary carcinoma all obviously increases, and male lung cancer M & M all accounts for first of all malignant tumor, and women's sickness rate accounts for second, and mortality rate accounts for second.The cause of disease of pulmonary carcinoma is still not exclusively clear and definite so far, and great mass of data shows, long-term a large amount of smoking and pulmonary carcinoma have very close relationship.Existing research proves: the probability that long-term a large amount of smoker suffers from pulmonary carcinoma is 10 ~ 20 times of non-smoker, and the age starting smoking is less, and the probability of suffering from pulmonary carcinoma is higher.
Pulmonary carcinoma has become the large killer threatening human health.According to domestic and foreign literature, the new cases of global pulmonary carcinoma, up to 205020, account for 14% of global various tumor new cases, have the feature of rate occurred frequently and high mortality.Under the many-side impact of the factors such as environmental pollution, smoking, ionizing radiation, occupational exposure and viral infection, sickness rate and the mortality rate of pulmonary carcinoma are in propradation always, increase with the speed of 0.5% every year, and along with the increase of smoking in adolescents number, pulmonary carcinoma is rejuvenation increasingly.According to China's Ministry of Public Health death survey result display in 2008, pulmonary carcinoma replaced hepatocarcinoma to become the first malignant tumor cause of the death of China.Therefore, the Diagnosis and Treat of pulmonary carcinoma causes the enough attention of medical circle.
Pulmonary carcinoma is divided into small cell lung cancer (SCLC, 20%) and nonsmall-cell lung cancer (NSCLC, 80%), and its pathogenic factor is complicated.At present both at home and abroad the treatment of pulmonary carcinoma is based on operation and radiotherapy, chemotherapy, but these methods easily cause larger side effect to the normal organ of patient, patient's prognosis and survival rate poor.The Chinese medicine being characteristic with " eliminating pathogenic factor for supporting vital QI " has played great function in treatment pulmonary carcinoma, and its curative effect is not only consolidated, and toxic and side effects is little, can not cause large injury to body, with chemotherapy also with the effect can playing efficacy enhancing and toxicity reducing.Therefore the anti-lung-cancer medicament finding and develop high-efficiency low-toxicity from Chinese medicine and natural drug is focus and the difficult point of oncology studies.Patent 2005100156241 discloses a kind of adjuvant therapy medicaments of advanced lung cancer, makes for raw material with the Radix Astragali, Radix Codonopsis, Radix Glehniae, Radix Ophiopogonis, Herba Agrimoniae, Rhizoma Bistortae, Herba Patriniae, Herba Hedyotidis Diffusae, Bulbus Fritillariae Cirrhosae, Radix Asteris, Radix Platycodonis, Semen Armeniacae Amarum, Chinese medicine of licorice root material extract.This invention dosage is large, and treatment cycle is long.Although method of the prior art has a variety of, be difficult to find effective method.
Summary of the invention
An object of the present invention is a kind of external used medicine for the treatment of pulmonary carcinoma, described pharmaceutical pack is containing following component: Ganoderma, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, natural Calculus Bovis, Radix Ophiopogonis, Herba Scutellariae Barbatae, Quercetin, Rhizoma Sparganii, Sargassum, Myrrha, Herba Agrimoniae, the Rhizoma Pinelliae, Fructus Forsythiae, Herba Solani Lyrati, Pumex and Semen Armeniacae Amarum.
Described medicine also comprises Fructus Cnidii, Rhizoma Menispermi and Herba Taraxaci.
Described medicine is by weight: Ganoderma 0.5-1 part, Radix Codonopsis 2-3.5 part, Rhizoma Atractylodis Macrocephalae 1-2 part, natural Calculus Bovis 0.6-0.8 part, Radix Ophiopogonis 1-1.5 part, Herba Scutellariae Barbatae 2-3 part, Quercetin 1-2 part, Rhizoma Sparganii 2.5-3 part, Sargassum 2.5-3.5 part, Myrrha 1-2 part, Herba Agrimoniae 1-3 part, Rhizoma Pinelliae 1-1.5 part, Fructus Forsythiae 1.2-1.6 part, Herba Solani Lyrati 3-4 part, Pumex 3-3.5 part, Semen Armeniacae Amarum 0.5-2 part, Fructus Cnidii 0.5-0.6 part, Rhizoma Menispermi 1-1.8 part and Herba Taraxaci 1-2 part.
Described medicine is by weight: Ganoderma 0.5 part, Radix Codonopsis 3 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, natural Calculus Bovis 0.7 part, Radix Ophiopogonis 1 part, Herba Scutellariae Barbatae 2 parts, Quercetin 1.5 parts, Rhizoma Sparganii 2.5 parts, Sargassum 3 parts, Myrrha 2 parts, Herba Agrimoniae 2 parts, the Rhizoma Pinelliae 1.5 parts, Fructus Forsythiae 1.5 parts, Herba Solani Lyrati 4 parts, Pumex 3 parts, Semen Armeniacae Amarum 1 part, Fructus Cnidii 0.5 part, Rhizoma Menispermi 1.6 parts and Herba Taraxaci 2 parts.
The preparation method of the external used medicine of described treatment pulmonary carcinoma, comprises the following steps:
(1) carry out micronizing to Ganoderma, cross 100 mesh sieves, reflux, extract, twice, obtains extracting solution and Ganoderma medicinal residues;
(2) water intaking 50 parts and xanthan gum 5 parts, be mixed and heated to 100 DEG C;
(3) get tristerin 5 parts, squalane 3 parts and stereth 4 parts and be mixed and heated to 90 DEG C;
(4) by step (2) and the mixing of step (3) gained solution, get the Ganoderma medicinal residues of step (1), mix with the drug component beyond claim 1 Ganoderma, stir, decoct more than 1 hour, the medicine soup obtained mixes with the extracting solution of step (1), and mixing temperature is 60 DEG C;
(5) cooling after mixing, air-dry, fill, obtains finished product.
The solvent of described reflux, extract, is ethanol and ethyl acetate; The volume ratio of ethanol and ethyl acetate is 5:1.
The rotating speed of described stirring is more than 500rpm/min.
The speed of described cooling is 1 DEG C/more than min.
Present invention employs leading micromolecule cutting technique, Ganoderma powder can be broken into molecule by micronizing.Utilize micromolecule cutting technique, the product cut size obtained is small, and the effective ingredient in medicine discharges fully with micromolecular form.Not containing the large section Plant fiber being difficult to Transdermal absorption, this product is not containing heavy metal simultaneously.Medicine can spread on affected part directly outward, and effective ingredient can without the need to the direct Transdermal absorption of carrier, and quick targeting arrives affected part.After reflux, extract, effectively the functional component in Ganoderma can be extracted, then decoct medicinal residues, farthest obtain the nutritional labeling in Ganoderma.Pharmaceutical composition in the present invention creates synergism, can play prophylaxis of tumours, and anticancer grows and then kills the effect of cancerous cell.The present invention obviously can also increase leukocytic number in patient body, improves immunity.Meanwhile, the present invention has no side effect, and suitable long-term taking, eradicates disease.
Detailed description of the invention
embodiment 1
(1) carry out micronizing to Ganoderma 0.5 part, cross 100 mesh sieves, reflux, extract, twice, solvent is ethanol and ethyl acetate; The volume ratio of ethanol and ethyl acetate is 5:1, obtains extracting solution and Ganoderma medicinal residues;
(2) water intaking 50 parts and xanthan gum 5 parts, be mixed and heated to 100 DEG C;
(3) get tristerin 5 parts, squalane 3 parts and stereth 4 parts and be mixed and heated to 90 DEG C;
(4) by step (2) and the mixing of step (3) gained solution, get the Ganoderma medicinal residues of step (1), with Radix Codonopsis 3 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, natural Calculus Bovis 0.7 part, Radix Ophiopogonis 1 part, Herba Scutellariae Barbatae 2 parts, Quercetin 1.5 parts, Rhizoma Sparganii 2.5 parts, Sargassum 3 parts, Myrrha 2 parts, Herba Agrimoniae 2 parts, the Rhizoma Pinelliae 1.5 parts, Fructus Forsythiae 1.5 parts, Herba Solani Lyrati 4 parts, Pumex 3 parts, Semen Armeniacae Amarum 1 part, Fructus Cnidii 0.5 part, Rhizoma Menispermi 1.6 parts and Herba Taraxaci 2 parts mixing, stir, speed of agitator is 500rpm/min, decoct 1 hour, the medicine soup obtained mixes with the extracting solution of step (1), mixing temperature is 60 DEG C,
(5) cooling after mixing, the speed of cooling is 1 DEG C/min, and air-dry, fill, obtains finished product.
embodiment 2
(1) carry out micronizing to Ganoderma 0.5 part, cross 100 mesh sieves, reflux, extract, twice, solvent is ethanol and ethyl acetate; The volume ratio of ethanol and ethyl acetate is 5:1, obtains extracting solution and Ganoderma medicinal residues;
(2) water intaking 50 parts and xanthan gum 5 parts, be mixed and heated to 100 DEG C;
(3) get tristerin 5 parts, squalane 3 parts and stereth 4 parts and be mixed and heated to 90 DEG C;
(4) by step (2) and the mixing of step (3) gained solution, get the Ganoderma medicinal residues of step (1), with Radix Codonopsis 3.5 parts, the Rhizoma Atractylodis Macrocephalae 1 part, natural Calculus Bovis 0.6 part, Radix Ophiopogonis 1.5 parts, Herba Scutellariae Barbatae 2 parts, Quercetin 2 parts, Rhizoma Sparganii 3 parts, Sargassum 2.5 parts, Myrrha 1 part, Herba Agrimoniae 1 part, the Rhizoma Pinelliae 1.5 parts, Fructus Forsythiae 1.2 parts, Herba Solani Lyrati 3 parts, Pumex 3.5 parts, Semen Armeniacae Amarum 0.5 part, Fructus Cnidii 0.5 part, Rhizoma Menispermi 1.8 parts and Herba Taraxaci 2 parts mixing, stir, speed of agitator is 600rpm/min, decoct 100 minutes, the medicine soup obtained mixes with the extracting solution of step (1), mixing temperature is 60 DEG C,
(5) cooling after mixing, the speed of cooling is 1.5 DEG C/min, and air-dry, fill, obtains finished product.
embodiment 3
(1) carry out micronizing to Ganoderma 0.8 part, cross 100 mesh sieves, reflux, extract, twice, solvent is ethanol and ethyl acetate; The volume ratio of ethanol and ethyl acetate is 5:1, obtains extracting solution and Ganoderma medicinal residues;
(2) water intaking 50 parts and xanthan gum 5 parts, be mixed and heated to 100 DEG C;
(3) get tristerin 5 parts, squalane 3 parts and stereth 4 parts and be mixed and heated to 90 DEG C;
(4) by step (2) and the mixing of step (3) gained solution, get the Ganoderma medicinal residues of step (1), with Radix Codonopsis 2 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, natural Calculus Bovis 0.8 part, Radix Ophiopogonis 1 part, Herba Scutellariae Barbatae 3 parts, Quercetin 1 part, Rhizoma Sparganii 2.5 parts, Sargassum 3.5 parts, Myrrha 2 parts, Herba Agrimoniae 3 parts, the Rhizoma Pinelliae 1 part, Fructus Forsythiae 1.6 parts, Herba Solani Lyrati 4 parts, Pumex 3 parts, Semen Armeniacae Amarum 2 parts, Fructus Cnidii 0.6 part, Rhizoma Menispermi 1 part and Herba Taraxaci 1 part mixing, stir, speed of agitator is 700rpm/min, decoct 1.5 hours, the medicine soup obtained mixes with the extracting solution of step (1), mixing temperature is 60 DEG C,
(5) cooling after mixing, the speed of cooling is 2 DEG C/min, and air-dry, fill, obtains finished product.
embodiment 4
(1) carry out micronizing to Ganoderma 0.6 part, cross 100 mesh sieves, reflux, extract, twice, solvent is ethanol and ethyl acetate; The volume ratio of ethanol and ethyl acetate is 5:1, obtains extracting solution and Ganoderma medicinal residues;
(2) water intaking 50 parts and xanthan gum 5 parts, be mixed and heated to 100 DEG C;
(3) get tristerin 5 parts, squalane 3 parts and stereth 4 parts and be mixed and heated to 90 DEG C;
(4) by step (2) and the mixing of step (3) gained solution, get the Ganoderma medicinal residues of step (1), with Radix Codonopsis 2.5 parts, the Rhizoma Atractylodis Macrocephalae 1.8 parts, natural Calculus Bovis 0.65 part, Radix Ophiopogonis 1.2 parts, Herba Scutellariae Barbatae 2.3 parts, Quercetin 1 part, Rhizoma Sparganii 2.9 parts, Sargassum 3.4 parts, Myrrha 1.6 parts, Herba Agrimoniae 2.5 parts, the Rhizoma Pinelliae 1.4 parts, Fructus Forsythiae 1.5 parts, Herba Solani Lyrati 3.2 parts, Pumex 3 parts, Semen Armeniacae Amarum 1.5 parts, Fructus Cnidii 0.6 part, Rhizoma Menispermi 1.6 parts and Herba Taraxaci 1.4 parts mixing, stir, speed of agitator is 550rpm/min, decoct 80 minutes, the medicine soup obtained mixes with the extracting solution of step (1), mixing temperature is 60 DEG C,
(5) cooling after mixing, the speed of cooling is 1.8 DEG C/min, and air-dry, fill, obtains finished product.
embodiment 5
(1) carry out micronizing to Ganoderma 1 part, cross 100 mesh sieves, reflux, extract, twice, solvent is ethanol and ethyl acetate; The volume ratio of ethanol and ethyl acetate is 5:1, obtains extracting solution and Ganoderma medicinal residues;
(2) water intaking 50 parts and xanthan gum 5 parts, be mixed and heated to 100 DEG C;
(3) get tristerin 5 parts, squalane 3 parts and stereth 4 parts and be mixed and heated to 90 DEG C;
(4) by step (2) and the mixing of step (3) gained solution, get the Ganoderma medicinal residues of step (1), with Radix Codonopsis 3 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, natural Calculus Bovis 0.6 part, Radix Ophiopogonis 1.4 parts, Herba Scutellariae Barbatae 2.5 parts, Quercetin 2 parts, Rhizoma Sparganii 3 parts, Sargassum 3 parts, Myrrha 1.5 parts, Herba Agrimoniae 1.5 parts, the Rhizoma Pinelliae 1 part, Fructus Forsythiae 1.3 parts, Herba Solani Lyrati 3.5 parts, Pumex 3.5 parts, Semen Armeniacae Amarum 1.5 parts, Fructus Cnidii 0.6 part, Rhizoma Menispermi 1 part and Herba Taraxaci 1.5 parts mixing, stir, speed of agitator is 650rpm/min, decoct 1.5 hours, the medicine soup obtained mixes with the extracting solution of step (1), mixing temperature is 60 DEG C,
(5) cooling after mixing, the speed of cooling is 2 DEG C/min, and air-dry, fill, obtains finished product.
Be comparative example 1 with patent 2005100156241.
Get the A/J mice in 6-8 age in week, often organize 10, with dosage lumbar injection every day 3, the 4-benzopyrene-corn oil of 10mg/kg body weight, there is pulmonary carcinoma in induction.Be divided into three groups: embodiment 1 group, embodiment 2 groups and comparative example 1 group, dosage is 0.5mg/kg body weight, continues medication 150 days.De-neck puts to death mice, to pulmonary's injection of formalin, calculates lung surface nodules number.
Table 1
As shown in Table 1, embodiments of the invention 1 and embodiment 2 lung surface nodules digital display work are less than comparative example 1, effectively can suppress the growth of lung carcinoma cell, reach the object of preventing and treating pulmonary carcinoma.
Take the logarithm trophophase A549 lung carcinoma cell, make its de-wall, re-suspended cell, cultivate in 48 hole quincuncial plates, every hole adds culture fluid 200ul, and dosage is 0.5/ml.Measure the growth inhibited effect of embodiment 1, embodiment 2 and comparative example 1 pair of tumor cell.
Table 2
As shown in Table 2, the growth of tumour cell suppression ratio of embodiment 1 and embodiment 2 is significantly higher than comparative example 1, effectively can suppress the proliferation activity of A549 lung carcinoma cell.
Above-mentioned detailed description is illustrating for one of them possible embodiments of the present invention, and this embodiment is also not used to limit the scope of the claims of the present invention, and the equivalence that all the present invention of disengaging do is implemented or changed, and all should be contained in the scope of technical solution of the present invention.
Claims (5)
1. treat the external used medicine of pulmonary carcinoma for one kind, it is characterized in that, the raw material medicaments in part by weight of described medicine is: Ganoderma 0.5-1 part, Radix Codonopsis 2-3.5 part, Rhizoma Atractylodis Macrocephalae 1-2 part, natural Calculus Bovis 0.6-0.8 part, Radix Ophiopogonis 1-1.5 part, Herba Scutellariae Barbatae 2-3 part, Quercetin 1-2 part, Rhizoma Sparganii 2.5-3 part, Sargassum 2.5-3.5 part, Myrrha 1-2 part, Herba Agrimoniae 1-3 part, Rhizoma Pinelliae 1-1.5 part, Fructus Forsythiae 1.2-1.6 part, Herba Solani Lyrati 3-4 part, Pumex 3-3.5 part, Semen Armeniacae Amarum 0.5-2 part, Fructus Cnidii 0.5-0.6 part, Rhizoma Menispermi 1-1.8 part and Herba Taraxaci 1-2 part;
The preparation method of the external used medicine of described treatment pulmonary carcinoma, comprises the following steps:
(1) micronizing is carried out to Ganoderma, reflux, extract, twice, obtain extracting solution and Ganoderma medicinal residues;
(2) water intaking 50 parts and xanthan gum 5 parts, be mixed and heated to 100 DEG C;
(3) get tristerin 5 parts, squalane 3 parts and stereth 4 parts and be mixed and heated to 90 DEG C;
(4) by step (2) and the mixing of step (3) gained solution, get the Ganoderma medicinal residues of step (1), mix with the drug component beyond the Ganoderma of claim 1, stir, decoct more than 1 hour, the medicine soup obtained mixes with the extracting solution of step (1), and mixing temperature is 60 DEG C;
(5) cooling after mixing, air-dry, fill, obtains finished product.
2. the external used medicine for the treatment of pulmonary carcinoma as claimed in claim 1; it is characterized in that, the raw material medicaments in part by weight of described medicine is: Ganoderma 0.5 part, Radix Codonopsis 3 parts, the Rhizoma Atractylodis Macrocephalae 2 parts, natural Calculus Bovis 0.7 part, Radix Ophiopogonis 1 part, Herba Scutellariae Barbatae 2 parts, Quercetin 1.5 parts, Rhizoma Sparganii 2.5 parts, Sargassum 3 parts, Myrrha 2 parts, Herba Agrimoniae 2 parts, the Rhizoma Pinelliae 1.5 parts, Fructus Forsythiae 1.5 parts, Herba Solani Lyrati 4 parts, Pumex 3 parts, Semen Armeniacae Amarum 1 part, Fructus Cnidii 0.5 part, Rhizoma Menispermi 1.6 parts and Herba Taraxaci 2 parts.
3. treat the external used medicine of pulmonary carcinoma as claimed in claim 1, it is characterized in that, the solvent of described reflux, extract, is ethanol and ethyl acetate; The volume ratio of ethanol and ethyl acetate is 5:1.
4. treat the external used medicine of pulmonary carcinoma as claimed in claim 1, it is characterized in that, the rotating speed of described stirring is more than 500rpm/min.
5. treat the external used medicine of pulmonary carcinoma as claimed in claim 1, it is characterized in that, the speed of described cooling is 1 DEG C/more than min.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510170402.0A CN104707047B (en) | 2015-04-13 | 2015-04-13 | A kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof |
| PCT/CN2016/074652 WO2016165495A1 (en) | 2015-04-13 | 2016-02-26 | Topical medicine for treating lung cancer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510170402.0A CN104707047B (en) | 2015-04-13 | 2015-04-13 | A kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104707047A CN104707047A (en) | 2015-06-17 |
| CN104707047B true CN104707047B (en) | 2015-12-02 |
Family
ID=53407091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510170402.0A Active CN104707047B (en) | 2015-04-13 | 2015-04-13 | A kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104707047B (en) |
| WO (1) | WO2016165495A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104707047B (en) * | 2015-04-13 | 2015-12-02 | 马建 | A kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof |
| CN105853483B (en) | 2016-03-30 | 2018-06-19 | 马建 | A kind of method with the micro- shear technology extraction Chinese medicine external application of small molecule |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101972454B (en) * | 2010-11-03 | 2011-10-05 | 何玉伟 | Medicament for treating lymphoma |
| CN102335374A (en) * | 2011-10-09 | 2012-02-01 | 许俊斋 | Medicine special for treating lung cancer |
| CN102772745B (en) * | 2012-08-21 | 2013-12-04 | 卢速江 | Chinese medicinal preparation for treating cancer and preparation method thereof |
| CN103055272A (en) * | 2013-01-29 | 2013-04-24 | 上海浦东高星生物技术研究所 | Aweisanpi plaster |
| CN104707047B (en) * | 2015-04-13 | 2015-12-02 | 马建 | A kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof |
-
2015
- 2015-04-13 CN CN201510170402.0A patent/CN104707047B/en active Active
-
2016
- 2016-02-26 WO PCT/CN2016/074652 patent/WO2016165495A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN104707047A (en) | 2015-06-17 |
| WO2016165495A1 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406245B (en) | A kind of brassiere containing Chinese yew | |
| CN102166338A (en) | Alpinia katsumadai-ginger composite, preparation method thereof and use thereof for preparing toxicity-attenuating and effect-increasing medicine for radiotherapy and chemotherapy of cancer | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN104707047B (en) | A kind of external used medicine for the treatment of pulmonary carcinoma and preparation method thereof | |
| Kan et al. | Natural-product-derived adjunctive treatments to conventional therapy and their immunoregulatory activities in triple-negative breast cancer | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN103550718B (en) | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma | |
| CN105596994A (en) | Medicine for treating lung cancer cell proliferation | |
| CN102406669B (en) | Chinese medicine composite and preparation method and medicinal preparation thereof | |
| CN1895337A (en) | Pharmaceutical use of Tangshen and Milkvetch root composition for improving late tumor patient life quality | |
| CN101391004B (en) | Medicine composition for treating late-stage esophageal carcinoma | |
| CN1187061C (en) | Application of sowthistle in preparing tobacco toxin resisting medicine | |
| CN102091313B (en) | Perilla leaf and ginger composition, its preparation method and its use in the preparation of cancer radiotherapy and chemotherapy drugs | |
| CN102091312B (en) | Ginger and Zanthoxylum bungeanum composition, its preparation method and its use in the preparation of drugs with attenuated toxicity and enhanced efficacy in cancer radiotherapy and chemotherapy | |
| CN105267793B (en) | A kind of new application of Chinese medicine composition | |
| JP2015515993A (en) | Pharmaceutical composition containing human cyclooxygenase and doxorubicin or doxorubicins, process for its preparation and use in the manufacture of multiple drugs | |
| CN104258046A (en) | Traditional Chinese medicine composition for treating non-small cell lung cancer with matching of TP scheme and preparation process of traditional Chinese medicine composition | |
| Wu et al. | Possible reduction of hepatoma formation by Smmu 7721 cells in SCID mice and metastasis formation by B16F10 melanoma cells in C57BL/6 mice by Agaricus blazei murill extract | |
| CN105477432A (en) | Medicine composition for treating tumors | |
| CN105194392A (en) | Pharmaceutical composition for preventing and treating tumors | |
| CN106668042A (en) | Application of Chonglou saponin VII to preparation of anti-lung-cancer medicament | |
| Pal et al. | Effect of poly herbal preparation HUMA on oral cancer: two case reports | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| TWI552758B (en) | Fermentation product of phellinus linteus,its use together with anticancer drugs for chemical treatment and method for preparing the same | |
| CN108721532A (en) | Chinese medicine composition for auxiliary treatment lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |